Ultimovacs ASA (OSL:ULTI) Common Stock : kr3.44 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Common Stock?

Ultimovacs ASA's quarterly common stock stayed the same from Jun. 2023 (kr3.44 Mil) to Sep. 2023 (kr3.44 Mil) but then increased from Sep. 2023 (kr3.44 Mil) to Dec. 2023 (kr3.44 Mil).

Ultimovacs ASA's annual common stock increased from Dec. 2021 (kr3.42 Mil) to Dec. 2022 (kr3.44 Mil) and increased from Dec. 2022 (kr3.44 Mil) to Dec. 2023 (kr3.44 Mil).

Ultimovacs ASA Common Stock Historical Data

The historical data trend for Ultimovacs ASA's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Common Stock Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

2.79

3.20

3.42

3.44

Ultimovacs ASA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															3.44	3.44	3.44	3.44	3.44

Ultimovacs ASA Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.